Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05118802
Other study ID # 21G.671
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 11, 2021
Est. completion date March 3, 2023

Study information

Verified date February 2024
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study identifies patient-important outcome measures and develops a survey that assesses the impact of nutritional interventions among cancer patients. Currently, data on the impact of medically tailored meals on outcomes that are meaningful to patients, providers, and payers are limited. For this reason, access to medically tailored meals as a covered benefit for cancer patients is limited. Thus, there is a need to explore the efficacy of nutritional interventions among this population. This study identifies outcome measures for nutritional interventions that are meaningful to patients and providers.


Description:

PRIMARY OBJECTIVES: I. To identify patient-important outcomes related to receiving nutrition services by engaging patients with cancer and clinicians. II. To conduct cognitive interviews to assess comprehension, acceptability, and appropriateness of patient-identified outcomes in aim 1. III. To pilot test the use of the nutrition-related outcome measures identified in aim 1 among a sample of oncology patients. OUTLINE: Part I: Patients and clinicians attend semi-structured interviews over 20-30 minutes or cognitive interviews over 60 minutes in support of survey refinement. Part II: Patients complete survey over 15 minutes.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date March 3, 2023
Est. primary completion date March 3, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - AIM 1 PATIENTS: SKCC oncology patients - AIM 1 PATIENTS: Currently receiving cancer treatment - AIM 1 PATIENTS: 18 years or older - AIM 1 PATIENTS: English speaking * Pending funding and staff abilities, efforts will be made to include other languages if possible - AIM 1 PATIENTS: 10 patients have received MANNA services in past 6 months - AIM 1 PATIENTS: 10 patients currently receiving cancer treatment for curative intent, screen positive for nutrition risk, and report food insecurity * Nutrition risk = a score of >= 2 on the Malnutrition Screening Tool, weight loss of 5% over 1 months, or weight loss of > 10% over 6 months - AIM 1 PATIENTS: 10 patients currently receiving cancer treatment for curative intent, screen positive for nutrition risk, and do not report food insecurity - AIM 1 CLINICIANS: Providing care/support for oncology patients - AIM 1 CLINICIANS: English speaking - AIM 2 PATIENTS: Current SKCC oncology patient - AIM 2 PATIENTS: 18 years or older - AIM 2 PATIENTS: English speaking - Pending funding and staff abilities, efforts will be made to include other languages if possible - AIM 2 PATIENTS: 3-5 patients have received MANNA services in past 6 months - AIM 2 PATIENTS: 3-5 patients currently receiving cancer treatment for curative intent, screen positive for nutrition risk, and report food insecurity * Nutrition risk = a score of >= 2 on the Malnutrition Screening Tool, weight loss > 5% over 1 month, or weight loss of > 10% over 6 months - AIM 2 PATIENTS: 3-5 patients currently receiving cancer treatment for curative intent, screen positive for nutrition risk, and do not report food insecurity - AIM 3 SKCC PATIENTS: Receiving active cancer treatment for curative intent - AIM 3 SKCC PATIENTS: Meet MANNA eligibility criteria - AIM 3 SKCC PATIENTS: Have a phone number or email address for contacting - AIM 3 SKCC PATIENTS: 18 years or older *Pending funding and staff abilities, efforts will be made to include other languages if possible - AIM 3 MANNA CLIENTS: Have any cancer diagnosis - AIM 3 MANNA CLIENTS: Currently receiving MANNA meals - AIM 3 MANNA CLIENTS: Have a phone number or email address for contacting - AIM 3 MANNA CLIENTS: 18 years or older - AIM 3 MANNA CLIENTS: English speaking * Pending funding and staff abilities, efforts will be made to include other languages if possible Exclusion Criteria: - AIM 1 PATIENTS: Unable to provide consent (as assessed by team member conducting enrollment, with use of teachback) - AIM 1 PATIENTS: Lives in a facility that provides nutrition services (e.g., nursing home, rehab facility, incarcerated, emergency shelter) - AIM 1 PATIENTS: Homelessness - AIM 1 CLINICIANS: Unable to provide consent (as assessed by team member conducting enrollment, with use of teachback) - AIM 2 PATIENTS: Unable to provide consent (as assessed by team member conducting enrollment, with use of teachback) - AIM 2 PATIENTS: Lives in a facility that provides nutrition services (e.g., nursing home, rehab facility, incarcerated, emergency shelter) - AIM 2 PATIENTS: Homelessness - AIM 3 SKCC PATIENTS: Unable to provide consent (as assessed by team member conducting enrollment, with use of teachback) - AIM 3 SKCC PATIENTS: Lives in a facility that provides nutrition services (e.g., nursing home, rehab facility, incarcerated, emergency shelter) - AIM 3 SKCC PATIENTS: Homelessness - AIM 3 MANNA CLIENTS: Unable to provide consent (as assessed by team members conducting enrollment, with use of teachback) - AIM 3 MANNA CLIENTS: Homelessness

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Interview
Attends Interviews
Survey Administration
Complete Survey

Locations

Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary identify patient-important outcomes related to receiving nutrition services by engaging patients with cancer and clinicians Reported as average time required to complete each assessment. At study completion; approximately 60 minutes
Primary Usability Reported as average time required to complete each assessment. At study completion; approximately 60 minutes
Primary Feasibility Reported as the number of participants who are able to complete the entire list of assessments to receive nutrition services. At study completion; approximately 60 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A